Clinical trial · Observational
Patient's Whole Process Follow-up Management(HOPE-1)
A Multicenter, Randomized, Open, Parallel Grouping, Investigator-initiated Study Evaluating the Long-term Benefit of Patients With Locally Advanced/Metastatic Non-small Cell Lung Cancer Followed up Using a Patient-wide Management Platform
NCT05339568CI-TRIAL-00060735HOPE-1recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
| Metastatic NSCLC | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients' whole process follow-up and management platform | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Platform follow-up cohort
- description
- This cohort will be managed and follow-up by patients' whole process follow-up platform. The patients can report the symptoms, get the reminder of the hospital visit, get the reminder of medicine taking, get the information of patients education.
- interventionNames
- Other: Patients' whole process follow-up and management platform
- label
- Routine follow-up cohort
- description
- This cohort will be managed and follow-up by the investigators or nurses. This cohort will take the routine follow-up and management way by the hospital.
Primary outcomes (1)
- measure
- Overall survival time
- timeFrame
- UP to 96 months
- description
- OS was calculated from the date of randomization to death from any cause.
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Fully understand the research and voluntarily sign the informed consent form (ICF) 2. Male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form. 3. The subject is diagnosed pathologically or cytologically with non-small cell lung cancer(NSCLC). 4. According to the 8th edition of the American Joint Committee on Cancer \[AJCC\], it is classified as stage IIB, stage III, stage IV NSCLC. 5. Not suitable for radical treatment or refuse surgery. 6. The life expectancy is not less than 3 months. 7. Be able to use a smartphone. Exclusion Criteria: 1. Patients with mental illness. 2. Presence of any other malignant tumor. 3. Patients who are expected to undergo radical surgery. 4. Currently participating in clinical trials. 5. Subjects who judged by the investigator to be unsuitable to participate in the trial.
References
Publications (0)
Data not yet available
No reference posted for this study.